Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.63%
1,044.40
-6.67
-0.63%
—1,051.071,046.551,057.891,042.67——
SIXC
Communications
SIXC
Communications
SIXC
-2.37%
569.41
-13.84
-2.37%
—583.25583.25583.25568.79——
SIXE
Energy
SIXE
Energy
SIXE
+1.59%
1,295.51
+20.30
+1.59%
—1,275.211,277.701,302.121,275.67——
SIXI
Industrials
SIXI
Industrials
SIXI
-2.32%
1,627.51
-38.60
-2.32%
—1,666.111,658.231,661.311,625.88——
SIXM
Financials
SIXM
Financials
SIXM
-0.57%
605.38
-3.48
-0.57%
—608.86607.95610.78603.35——
SIXR
Staples
SIXR
Staples
SIXR
-0.44%
821.48
-3.65
-0.44%
—825.13825.12832.42820.53——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.05%
198.39
+0.090
+0.05%
—198.30198.30199.82197.25——
SIXT
Technology
SIXT
Technology
SIXT
-3.14%
2,669.58
-86.42
-3.14%
—2,756.002,727.872,729.882,668.52——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.23%
919.05
+2.10
+0.23%
—916.95917.31921.78912.88——
SIXV
Health care
SIXV
Health care
SIXV
-0.34%
1,474.76
-4.99
-0.34%
—1,479.751,478.541,486.621,473.75——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.75%
2,200.00
-39.08
-1.75%
—2,239.082,228.382,241.812,198.75——
AJANTPHARM:NSE
Ajanta Pharma Ltd
₹2,880.00
+0.59%
(+16.80) 1D
Mar 25, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for AJANTPHARM...
Open
₹2,910.00
High
₹2,957.80
Low
₹2,864.60
Mkt. cap
359.80B
Avg. vol.
116.95K
Volume
88.70K
Dividend
1.46%
Quarterly dividend
₹10.50
Ex dividend date
Nov 10, 2025
P/E ratio
35.47
52-wk high
₹3,228.00
52-wk low
₹2,327.30
EPS
₹81.21
Shares outstanding
88.45M
No. of employees
10K
News stories
From sources across the web
Profile
Ajanta Pharma Limited is an Indian multinational pharmaceutical company. The company operates in India, the United States, and over 30 countries across Africa, Southeast Asia, West Asia, and the CIS. It was established in 1973.. Wikipedia
About Ajanta Pharma Ltd
CEO-
Employees9.63K
Founded1973
Headquarters-
SectorPharmaceutical industry
Websiteajantapharma.com
Last report
Jan 30, 2026
Fiscal Period
Q3 2026
Normalized EPS / Estimate
21.91/ (19.84 est.)INR
+10.45%beat
Revenue / Estimate
13.75B/ (13.04B est.)INR
+5.46%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
11.70B
13.03B
13.54B
13.75B
Cost of goods sold
3.56B
2.76B
3.17B
2.86B
Cost of revenue
3.56B
2.76B
3.17B
2.86B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.95B
3.03B
3.17B
3.31B
Operating expense
5.58B
6.92B
7.11B
7.50B
Total operating expenses
9.14B
9.67B
10.28B
10.36B
Operating income
2.57B
3.35B
3.26B
3.39B
Other non operating income
-460.40M
169.50M
197.10M
164.20M
EBT including unusual items
2.69B
3.31B
3.41B
3.59B
EBT excluding unusual items
2.67B
3.31B
3.41B
3.59B
Income tax expense
441.50M
757.90M
806.20M
848.30M
Effective tax rate
16.39%
22.89%
23.66%
23.66%
Other operating expenses
2.24B
3.47B
3.51B
3.76B
Net income
2.25B
2.55B
2.60B
2.74B
Net profit margin
19.25%
19.60%
19.22%
19.91%
Earnings per share
18.00
20.43
20.82
21.91
Interest and investment income
471.60M
-
-
-
Interest expense
-60.70M
-52.60M
-33.90M
-51.00M
Net interest expenses
410.90M
-52.60M
-33.90M
-51.00M
Depreciation and amortization charges
397.80M
412.90M
429.70M
435.10M
EBITDA
2.88B
3.66B
3.68B
3.70B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer